Erythromycin (EM), a macrolide antibiotic has been recently reported to depress the extent of inflammation irrespective of its antimicrobial action. Our study was initiated to examine the effect of EMon T cell proliferation in vitro, since other macrolide antibiotics FK506and rapamycin (RAP) have been well known to possess strong immunosuppressive or anti-inflammatory potential. EMhad a suppressive effect on the proliferative response of humanlymphocytes stimulated with mitogens and antigens, while EMhad no effect on concanavalin A (Con A)-induced interleukin-2 (IL-2) production or IL-2Ra (CD25) expression. Delayed addition ofEM after the first 48 hours ofmitogenic stimulation did suppress IL-2-dependent proliferation of Con A blasts, whereas pretreatment with EMfor the first 48 hours of stimulation did not impede the subsequent IL-2-dependent proliferation of obtained blast cells. The results indicate that EMsuppresses T cell proliferation at a late stage in the activation process by impairing their response to IL-2. This antilymphocytic action of EM was quite distinct from that of FK506 or cyclosporin A (CsA) but was similar to that of RAP. Unlike RAP, however, EMdid not antagonize FK506-induced suppression but potentiated the action of FK506and CsA. The addition of an enteric hormonemotilin, a receptor of which was previously found to be occupied by EM, unaffected the lymphocyte proliferation and the subsequent EM-induced suppression. These data suggest that EMoperates through an undefined mechanism probably distinct from that of FK506, CsA, RAPor motilin.
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The usage of antibiotics is generally based on the concept of their selective toxicity to the target organisms and extensive studies have been directed towards specific effects of antimicrobial agents on pathogens. However, recent observations indicate that certain antibiotics alter the function of host cells
Erythromycin (EM) is a macrolide antibiotic first isolated from cultures of Streptomyces erythreus in 1952 and has been widely used to treat a variety of infectious diseases3). In the past several years, it was reported that long-term treatment with EMappears to improve chronic inflammatory process including diffuse panbronchiolitis4'5), bronchial asthma6) and HTLV-1-associated myelopathy7), irrespective of its antimicrobial property.
There is increasing evidence that EMhas direct effects on host cells. To date, it has been reported that EMinfluences neutrophil functions8'9* and reduces mucus secretion from secretory epithelial cells10) and contracts gastrointestinal smooth muscles binding to a receptor of an enteric hormone, motilin1 1}.
Although previous work demonstrated that EM suppressed a mitogen-mediated lymphocyte proliferative response12'13), the antilymphocytic activity of EMwas never fully studied. On the other hand, the macrolide antibiotics FK506 and rapamycin (RAP) were isolated from other strains of Streptomyces VOL.46 NO.9 THE JOURNAL OF ANTIBIOTICS 1 407 and are nowwell knownto possess strong immunosuppressive or anti-inflammatory activity14~19). The aim of this study was to investigate the antilymphocytic action of EMand characterize the bioactivity, comparing with those of other immunosuppressants. Wedemonstrate that the antilymphocytic activity of EMis mild and that the property is quite distinct from that of FK506 or cyclosporin A (CsA) but similar to that of RAP.
Materials and Methods

Reagents
Erythromycin base was obtained from Dainippon Pharmaceutical Co., Ltd. (Osaka, Japan heat-inactivated fetal calf serum (Z. L. Bockneck Laboratories Inc., Ontario, Canada), 2 mML-glutamine, 100/zg/ml streptomycin and lOOu/ml penicillin at 37°C in a humidified 5% CO2 atmosphere.
Cell Lines
The human T-lymphoid (Molt-4, Jurkat and HPB-ALL), monocytic leukemia (THP-1) and melanoma (A375) cell lines were maintained in the mediumdescribed above.
Proliferation Assay PBMC(5 x 105/ml) were cultured in 96-well flat-bottom tissue culture plates (Falcon No. 3072; Becton Dickinson Labware, Lincoln Park, NJ) and were stimulated with Con A (2 jug/ml) or PPD (50 u/ml) in the absence or presence of EMfor 72 hours. EMwith each stimulus was added at the initiation of the cultures. The percentage of viable cells was determined by trypan blue dye exclusion test. Mixed lymphocyte reactions (MLR) were established between PBMC(5 x 105/ml) from pairs of donors and these cultures were incubated in the absence or presence of EMfor 5 days.
To examine the effects of exogenous IL-1, IL-2 and prostaglandin E2 (PGE2), recombinant human IL-1 (10-100u/ml), IL-2 (100u/ml) or indomethacin (5 x 10~6m) together with EM(l~100/zg/ml) was added to the system of Con A-stimulated proliferation of PBMC.
Each culture was pulsed with 0.5 fid of [3H]thymidine (New England Nuclear, Boston, MA) per well for the final 1 8 hours of incubation before being harvesting onto glass fiber filters. The radioactivity collected was counted by a liquid scintillation counter14). Results are expressed as the mean + SD.
Preparation and IL-2-Dependent Proliferation of Con A Blasts
PBMCwere stimulated with Con A (2 /ig/ml) for 48 hours and the non-adherent cells were collected and washed in phosphate buffered saline containing methyl a-mannopyranoside (25 him) to eliminate further effect of Con A. Then obtained blast cells (Con A blasts) were incubated with exogenous IL-2 in the absence or presence of EM(1~100/ig/ml) for 96 hours.
Analysis of Lymphocyte Surface Markers
For the lymphocytesurface marker study, cells were cultured in tissue culture dishes (Falcon 3003, Becton Dickinson Labware) at 1 x 106/ml for 24~48 hours. Surface markers oflymphocytes were examined by using anti leu-4 (CD3), anti leu-3a (CD4), anti leu-2a (CD8) or anti-Tac (CD25) (Becton Dickinson Mountain View, CA) with fluorescein isothiocyanate-conjugated goat anti-mouse IgG F(ab')2 fragment (Cooper Biomedical Inc., Malverm, PA). Flow cytometry was performed on a FACStar (Becton Dickinson)14).
Human IL-2 ELISA Assay The amount of IL-2 produced by cultured PBMCwas determined using a ELISA system specific for IL-2 (E. I. Du Pont de Nemours & Co., Medical Products Department, Boston, MA). Cell-free culture supernatants of Con A-stimulated PBMC(5 x 105/ml) after 48 hours of incubation in the presence of EM or FK506were assayed to the manufacturer's instructions20*. Samples were assayed in triplicate and analyzed on an automated ELISA plate reader (SJeia Auto Reader, model ER-80000, Sanko Junyaku Co., Ltd., Tokyo, Japan). The detection limit of this ELISA kit was 0.5IU/ml of IL-2.
Statistical analysis was performed using Student's Mest.
Results
EMSuppresses the Proliferative Response Induced by Con A, PPD and MLR in Human T Cells To determine whether EMhas antilymphocytic activity, we first evaluated the effects of EMon the proliferative response of humanT cells stimulated with a mitogen (Con A), an exogenous antigen (PPD) and alloantigens (MLR). EMdose-dependently suppressed [3H]thymidine incorporation by 10~20% at 1 jug/ml (p<0.01) and by 40-60% at 100^g/ml (p<0.001) in each system ( Fig. 1(A) , (B) and (C)). Another lectin, phytohemagglutinin (PHA)-mediated proliferation was also suppressed by EM(data not shown). The percentage of viable cells did not change after 48~72 hours of incubation in the presence of EMand the final concentration of the diluent, 0.05% ethanol in the mediumhad no suppressive effect in this system (data not shown).
EMdoes not Suppress IL-2 Production or IL-2Ra (CD25) Expression To explore the antilymphocytic action, we next examined a possibility that impairment of IL-1 or IL-2 production or enhancement of PGE2 production causes EM-induced suppression.
However, recombinant human IL-1, IL-2 or indomethacin did not reverse EM-induced suppression of Con A-stimulated lymphocyte proliferation (data not shown). Another immunosuppressive macrolide FK506 is known to inhibit IL-2 production markedly14'19), Thus, we further evaluated whether EMdirectly influences IL-2 production. The amount of IL-2 in the culture supernatants of Con A-stimulated PBMC was measured by IL-2 ELISA. However, EM (l~100/ig/ml) did not suppress IL-2 production by Con A-stimulated PBMC, while FK506 (i nM) did suppress IL-2 production by 90% (data not shown). The surface expression of CD25on lymphocytes stimulated with ConA in the absence or presence of EMwas also evaluated. Although EM( 100^g/ml) suppressed Con A-stimulated lymphocyte proliferation by 40~60% as shown in Fig. 1(A) , it did not reduce fluorescence intensity of CD25 on Con A-stimulated lymphocytes (data not shown).
EMSuppresses the Lymphocyte Proliferative Response at the Late Stage of T Cell
Activation, Impairing Their Response to To elucidate the target phase of EM-mediated suppression, the time-course studies were carried out. Con A-stimulated human T cells began to incorporate [3H]thymidine within 24~48 hours to a peak rate ofDNAsynthesis at 72~96 hours. Addition of EMdid not cause any major alteration in these kinetics but the peak height was reduced (53.7+7.4x 10~3cpm; 57%; /?<0.01) as compared to control response (93.7+ 10.7 x 10"3 cpm). When EMwas added to the culture after 24hours from stimulation, the suppression was observed to the same degree (data not shown).
To further clarify the stage of T cell activation suppressed by EM, we examined whether IL-2-dependent growth of Con A-stimuiated lymphocytes is directly suppressed by EM. Con A blasts were prepared as described before. As shown in Fig. 2 , IL-2-dependent proliferation of Con A blasts was dose-dependently suppressed by EM. As compared with the suppressive effect of EM(100//g/ml) on their IL-2-dependent growth, wThen PBMCwere pretreated with EM(100 /zg/ml) and rinsed, the subsequent IL-2-dependent proliferation was not hampered (/?<0.01). Taken together, these results indicate that EMsuppresses the stage of IL-2-dependent T cell proliferation.
To determine whether EMinterferes with factors-independent cell proliferation, effects of EMon the autonomous proliferation of several human cell lines were examined. The proliferation of THP-1, A375, HPB-ALLand Molt-4 cells was unaffected by EM(data not shown). Only at high concentrations of EM (100^g/ml), [3H]thymidine incorporation to Jurkat cells was slightly suppressed (1 5%; /? < 0.05), although the suppression ratio was significantly lower than that in the proliferative response of normal lymphocytes induced by Con A (41%; p<0.001).
Additive Effect of EMon the Inhibition of Lymphocyte Proliferative
Response by FK506 or CsA The antilymphocytic action of EMwas found to be similar to that of another immunosuppressive macrolide RAP, which was previously shown to impair IL-2-driven T cell proliferation with minimal effect on IL-2 production and IL-2R expression18>19). Interestingly, recent studies have revealed that RAPacts as an antagonist of FK506suppression and interacts with a common receptor site(s) of FK5062122). Thus, we examined whether EMalso acts as an antagonist of FK506or CsA. Unlike RAP-inducedsuppression, however, percent suppression is 26% at EM10/ig/ml, 51% at FK506 0.1nM and 71% at EM10/xg/ml plus FK506 0.1nM. Percent suppression is 18% at EM10/xg/ml, 20% at CsA 1nM and 45% at EM 10/zg/ml plus CsA 1 nM (Fig. 3) . These indicate that the combination of EMand FK506 exerts additive inhibitory effect on the proliferative response, as well as the combination of EMand CsA.
Motilin, an Enteric Hormone does not Suppress Lymphocyte Proliferation and does not Reverse EM-Induced Suppression EMwas reported to bind to a receptor of an enteric hormone, motilin11}. Although it is unlikely that VOL.46 NO.9 THE JOURNAL OF ANTIBIOTICS 1411 lymphocytes have motilin receptors on their surfaces, it could not be ruled out that EMbinds to an unknownreceptor structurally similar to the motilin receptor and suppresses the lymphocyteproliferation. However, motilin neither suppressed lymphocyte proliferation even at high concentrations (0.01~10 fiu) nor had a potential to reverse EM-induced suppression (data not shown).
Discussion
The present investigation provides the notion that EMpossesses the potency to suppress lymphocyte proliferative response in vitro. EMsuppressed the proliferation of humanT cells induced by antigens (PPD or alloantigens) as well as mitogens (Con A or PHA) in a dose-dependent manner.
The antilymphocytic activity of two other macrolides, FK506and RAPare quite different each other; FK506 strongly suppresses the early phase of T cell activation, like CsA, inhibiting IL-2 production and IL-2 receptor expression, while RAPprimarily suppresses the stage of IL-2-dependent proliferation with minimal effect on IL-2 production or IL-2 receptor expression14'18'19>22). In our present studies, exogenous IL-2 could not overcome EM-induced suppression. IL-2 production and IL-2 receptor (CD25) expression induced by Con A were not suppressed by EM. The kinetic studies disclosed that EMdid not alter the timing of the beginning of DNAsynthetic phase but reduced the [3H]thymidine incorporation.
The experiment of Con A blasts demonstrated that EMaffects the late phase of T cell activation suppressing IL-2-dependent proliferation. Collectively, these properties of EMare quite distinct from those of FK506 or CsAbut similar to those of RAP.
The proliferation of several cell lines was unaffected by EM,although the proliferation of a T-lymphoid Jurkat cell line was slightly affected by EM.Similarly, RAPwas shown to have little or no antiproliferative activity against several tumor lines23), while RAPwas reported to suppress the autonomous proliferation of a T cell hybridoma line19). A possibility that EMacts as a nonspecific cytotoxic agent seems unlikely, since even high concentrations of EMused did not reduce cell viability by trypan blue dye exclusion test and the pretreatment with EMunaffected the subsequent lymphocyte proliferation (the last column in Fig.  2 ). It has been reported that efflux of EMfrom mammaliancells after removal of the extracellular drug from tissue culture medium is rapid3).
A possible effect of EMon contaminating monocytes seems negligible since EMsimilarly suppressed the proliferative response of non-adherent cells or Con Ablasts without adherent cells. At least IL-1 and PGE2released from accessory cells appear to have little contribution to this suppression mechanism.In addition, a possibility that EMmodifies membrane-associated events of T cell activation including interaction between T cells and accessory cells is unlikely because our preliminary study revealed that human lymphocyte proliferation induced by phorbol myristate acetate (PMA) and ionomycin which bypass the early membrane-associated step of T cell activation240, was equally suppressed by EM(data not shown). Although a possibility that EMacts selectively on a certain T cell subset should be considered, at least the proportion of CD4 or CD8 positive lymphocytes was unaffected by EM(data not shown) and memory T cell proliferation by PPD and non-specific T cell proliferation by Con A were equally suppressed by EM as shown in Fig. 1 .
Recent studies have shown that RAP competitively inhibits the activity of peptidylprolyl isomerase characterized as the major cytosolic FK506-binding protein (FKBP) and that RAPacts as an antagonist of FK50621'25). The analogy between RAPand EMprompted us to examine the combined effects of EM and other immunosuppressants.
However, EM had an additive effect of FK506-or CsA-induced suppression. It is inferred that EMdoes not competitively bind to the cellular target(s) of FK506 or CsA. It is likely that RAPafter binding to FKBPinteracts another target molecule and suppresses a pathway of the late phase of T cell activation25) and it was recently reported that the p70 S6 kinase activation cascade is blocked by the FKBP-RAPcomplex26). As compared with RAP, much higher concentrations of EMare needed to exert significant immunosuppressive effect, nevertheless, it should be further studied whether RAPand EMshare the same target for their similar biological actions.
A putative target molecule of EMon lymphocytes dose not appear to be analogous to the motilin receptor which was reported to be occupied by EM11},because the motilin at muchhigher concentrations SEPT. 1993 than those (> 1 iim) to contract smooth muscles had no effect on the proliferation of T cells.
In our study, the antilymphocytic effect of EMat therapeutic concentrations (0.5~2 /zg/ml) was much less potent than that of FK506 or RAP, but the suppression was dose-dependent. Since EMis well known to be accumulated into tissue cells9), long-term treatment with EMmight exert its effect on infiltrating lymphocytes at sites of chronic inflammation.
